Trial Profile
A Multi-center, Prospective, Randomized, Double-blind Study to Assess the Impact of Sacubitril/Valsartan vs. Enalapril on Daily Physical Activity Using a Wrist Worn Actigraphy Device in Adult Chronic Heart Failure Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms OUTSTEP-HF
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 13 Dec 2020 Primary endpoint has not been met. (Change From Baseline (Week 0) in Mean Daily Non-sedentary Daytime Activity at End of Study (Week 12))
- 13 Dec 2020 Primary endpoint has not been met. (Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12))
- 13 Dec 2020 Results published in the European Journal of Heart Failure